CellCept is manufactured by Genentech, a member of the Roche Group [1].
What is CellCept used for?
CellCept, with the active ingredient mycophenolate mofetil, is a medication used to prevent the body from rejecting a transplanted organ, such as a kidney, liver, or heart [2]. It works by suppressing the immune system, specifically targeting the lymphocytes that can cause organ rejection [2].
How does mycophenolate mofetil work?
Mycophenolate mofetil is an immunosuppressant that inhibits inosine monophosphate dehydrogenase (IMPDH) [3]. This enzyme is crucial for the de novo synthesis of guanosine nucleotides, which are essential for lymphocyte proliferation. By blocking IMPDH, mycophenolate mofetil reduces the production of these nucleotides, thereby suppressing the immune response that leads to organ rejection [3].
When does the patent for CellCept expire?
The patent exclusivity for CellCept has already expired in many markets, allowing for the availability of generic versions [4]. Information on specific patent expiry dates can be complex and vary by region, but DrugPatentWatch.com tracks such data [4].
Can generic versions of CellCept be used?
Yes, generic versions of CellCept are available and are bioequivalent to the brand-name drug [5]. These generic options, containing mycophenolate mofetil, offer a more affordable alternative for patients [5].
What are the potential side effects of CellCept?
Common side effects associated with CellCept include diarrhea, nausea, vomiting, and abdominal pain [2]. More serious side effects can involve an increased risk of infections due to the immunosuppression, as well as potential for certain types of cancer [2]. Patients should discuss any concerns with their healthcare provider.
Who are the main competitors to CellCept?
Besides generic versions of mycophenolate mofetil, other immunosuppressants used for organ transplantation include tacrolimus and sirolimus [6]. These drugs operate through different mechanisms to manage the immune system and prevent rejection [6].
Sources:
[1] https://www.gene.com/media/press-releases/display? PR=1100
[2] https://www.nhs.uk/medicines/mycophenolate-mofetil/
[3] https://www.ncbi.nlm.nih.gov/books/NBK556021/
[4] https://drugpatentwatch.com/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681511/
[6] https://www.hopkinsmedicine.org/health/treatment- Best-practices/immunosuppression-after-transplantation